Department of Clinical Laboratory, Chengdu Public Health Clinical Centre, Chengdu610016, Sichuan Province, PR China.
West China School of Public Health/West China Fourth Hospital, Sichuan University, Chengdu610041, Sichuan Province, PR China.
Epidemiol Infect. 2022 Jan 28;150:e27. doi: 10.1017/S0950268822000127.
We investigated the drug resistance of Mycobacterium tuberculosis isolates from patients with tuberculosis (TB) and HIV, and those diagnosed with only TB in Sichuan, China. TB isolates were obtained from January 2018 to December 2020 and subjected to drug susceptibility testing (DST) to 11 anti-TB drugs and to GeneXpert MTB/RIF testing. The overall proportion of drug-resistant TB (DR-TB) isolates was 32.1% (n = 10 946). HIV testing was not universally available for outpatient TB cases, only 29.5% (3227/10 946) cases had HIV testing results. The observed proportion of multidrug-resistant TB (MDR-TB) isolates was almost double than that of the national level, with approximately 1.5% and 0.1% of the isolates being extensively drug resistant and universally drug resistant, respectively. The proportions of resistant isolates were generally higher in 2018 and 2019 than in 2020. Furthermore, the sensitivities of GeneXpert during 2018-2020 demonstrated a downward trend (80.9, 95% confidence intervals (CI) 76.8-85.0; 80.2, 95% CI 76.4-84.1 and 75.4, 95% CI 70.7-80.2, respectively). Approximately 69.0% (7557/10 946) of the TB cases with DST results were subjected to GeneXpert detection. Overall, the DR-TB status and the use of GeneXpert in Sichuan have improved, but DR-TB challenges remain. HIV testing for all TB cases is recommended.
我们调查了中国四川的结核病(TB)和 HIV 患者以及仅诊断为结核病的结核分枝杆菌分离株的耐药情况。从 2018 年 1 月至 2020 年 12 月,我们获得了结核分枝杆菌分离株,并对 11 种抗结核药物进行了药物敏感性测试(DST)和 GeneXpert MTB/RIF 测试。耐药结核病(DR-TB)分离株的总体比例为 32.1%(n=10946)。门诊结核病病例并非普遍进行 HIV 检测,仅有 29.5%(3227/10946)的病例有 HIV 检测结果。观察到的耐多药结核病(MDR-TB)分离株的比例几乎是全国水平的两倍,分别约有 1.5%和 0.1%的分离株为广泛耐药和完全耐药。2018 年和 2019 年耐药分离株的比例普遍高于 2020 年。此外,2018-2020 年期间,GeneXpert 的敏感性呈下降趋势(80.9%,95%置信区间[CI]76.8-85.0;80.2%,95%CI 76.4-84.1 和 75.4%,95%CI 70.7-80.2)。有 DST 结果的结核病病例中,约有 69.0%(7557/10946)进行了 GeneXpert 检测。总体而言,四川的 DR-TB 状况和 GeneXpert 的使用有所改善,但 DR-TB 仍面临挑战。建议对所有结核病病例进行 HIV 检测。